Item List

EIN News
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Recent Posts

Portfolio Company


Physician Burnout Has Reached Distressing Levels, New Research Finds ...

New York Times

General News


Private Equity Sees the Billions in Eye Care as Firms Target High-Profit Procedu ...

Kaiser Family Foundation

General News


CIOs look forward to Big Tech, digital health collaborations ...

Beckers Hospital Review

surf break copy_edited_edited.jpg